CD163 and neoplasm: We employed immunostaining for CD3, CD4, CD8, Granzyme B (GzmB), FOXP3, CD163, and CD68 markers to quantitively analyze the STR patient’s tumor immune landscape both at baseline and during STR (Fig. 2)10–12.